Trial Profile

Phase Ib 12-week, randomized, placebo-controlled study of MET409 in patients with non-alcoholic steatohepatitis (NASH)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 22 Feb 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MET-409 (Primary)
Indications Non-alcoholic steatohepatitis
Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Proof of concept

Most Recent Events

16 Feb 2021 Results published in the Metacrine Media Release.
10 Feb 2021 Results published in the Journal of Hepatology
01 Oct 2020 According to a Metacrine media release, data will be presented the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting Digital Experience.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com